Auspex Pharmaceuticals Report issue

Contributed to NME For profit Phase 3
Founded: La Jolla CA United States (2001)
Status: Acquired by Teva (2015)

Organization Overview

First Clinical Trial
2013
NCT01897896
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Auspex Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

deutetrabenazine (austedo) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chorea (Phase 3)

Dyskinesias (Phase 3)

Huntington Disease (Phase 3)

Syndrome (Phase 1)

Tardive Dyskinesia (Phase 3)

Tourette Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1